ZNTL (Zentalis Pharmaceuticals) Moat Score: 5/10 (As of Jul. 08, 2026)


ZNTL Zentalis Pharmaceuticals Inc ZNTL
30 GF Score
Price $4.74
! 3 Warning Signs
View Full Analysis

What is Zentalis Pharmaceuticals Moat Score?

Zentalis Pharmaceuticals ZNTL -0.84% 30 Moat Score is 5 as of Jul. 08, 2026. GuruFocus rates ZNTL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,393 Biotechnology companies, Zentalis Pharmaceuticals ranks better than 96.7% on this metric.

Zentalis Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Zentalis Pharmaceuticals has Narrow Moat: Zentalis has a solid narrow moat with valuable intellectual property and strong R&D capabilities in oncology, but faces significant competition and regulatory hurdles.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zentalis Pharmaceuticals might have Narrow Moat - Solid narrow moat.

Zentalis Pharmaceuticals  (NAS:ZNTL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zentalis Pharmaceuticals Moat Score Related Terms

ZNTL vs ELDN, GLSI, SABS: Moat Score Comparison

For the Biotechnology subindustry, Zentalis Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zentalis Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's Moat Score falls into.


ZNTL
30GF Score
Zentalis Pharmaceuticals Inc ZNTL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Zentalis Pharmaceuticals (ZNTL) has a Moat Score of 5 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zentalis Pharmaceuticals ranks #46 out of 1393 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Zentalis Pharmaceuticals' Moat Score too high?
Zentalis Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Zentalis Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, Zentalis Pharmaceuticals ranks #46 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zentalis Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zentalis Pharmaceuticals' Moat Score compare to ELDN and GLSI?
According to the Biotechnology industry distribution chart, Zentalis Pharmaceuticals ranks #46 out of 1393 companies for Moat Score. This places Zentalis Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Zentalis Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zentalis Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zentalis Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentalis Pharmaceuticals stock overvalued right now?
Zentalis Pharmaceuticals (ZNTL) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Zentalis Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zentalis Pharmaceuticals (ZNTL), the current Moat Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zentalis Pharmaceuticals Business Description

Address 10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
30GF Score

Get the complete analysis for ZNTL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.74
Price